Leading well-being enhancement company
Healthways
(
HWAY
) and Carondelet Health Network recently revealed an agreement to
study possibilities in population health management in the Tucson
region of Arizona. Both organizations recognize the need for
health care systems to come up with new abilities to enhance the
condition of members in a community.
Carondelet is the biggest Catholic health system operating in
Arizona. It is a component of Ascension Health set up by the
Sisters of St. Joseph of Carondelet in 1880.
The Healthways model encourages people to make favorable
lifestyle changes that lead to enhanced well-being, reduced
healthcare costs, improved performance and economic value for
customers. The company has invested in technology platforms that
provide scalable support for large populations. It has tie-ups
with a large proportion of U.S. health plans and counts many
millions of lives in its customer base.
Due to its unique scalable business model, Healthways shares
may present a long-term investment opportunity, although it faces
many challenges in the short term.
Healthways is the leader in a strategically critical and
rapidly evolving part of the health care services market. Its
fitness program (SilverSneakers) for seniors is available at over
15,000 centers across the U.S. and caters to over nine million
eligible enrollees.
The SilverSneakers Fitness Program encourages older people to
regularly exercise, thereby reducing healthcare expenses and
enhancing well being. The program promotes positive changes in
behavior by meshing social encounters with its fitness regimen.
Healthways competes with
Express Scripts Holding Company
(
ESRX
) among others.
Currently, Healthways retains a Zacks Rank #3 (Hold).
Air Methods Corp.
(
AIRM
) and
Covance Inc.
(
CVD
) carry a Zacks Rank #2 (Buy) and are expected to do
well.
AIR METHODS CRP (AIRM): Free Stock Analysis
Report
COVANCE INC (CVD): Free Stock Analysis Report
EXPRESS SCRIPTS (ESRX): Free Stock Analysis
Report
HEALTHWAYS INC (HWAY): Free Stock Analysis
Report
To read this article on Zacks.com click here.
Zacks Investment
Research